SecBot SecBot

MXCT

MAXCYTE, INC.
Nasdaq· Services-Commercial Physical & Biological Research· Inc. DE· CIK 0001287098 Biotech & Drug Discovery
$1.49 +0.09 (+6.07%)
Oct 26 4:00 PM ET · prev $1.40
Market cap
$147.6M
Micro cap
Median target
$4.50
+203% · range $2.43–5.00
Next earnings
Nov 10
in 15 days · EPS est. −$0.08
1 year
−3.6%
from $1.54 · Oct 27
30 days
+28.0%
from $1.16
52-week range
$0.6760–1.76
−16% from high · low Mar 30
Avg volume 20D
1.36M
Oct 14 spike 12.67M
Short interest
1.09M
≈1.1% of shares · −6.9%
Days to cover
3.1
at average volume
Insider net
−$8.3K
0 buyers · 1 seller · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
3
analyzed by SecBot
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Liontrust Investment Partners LLP, a UK-based investment firm, filed a Schedule 13D disclosing beneficial…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider sold $8.3K.

  • InstitutionsMIXED

    Q2 2026: 23 added (0 new), 18 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.075 → −$0.083 over 90 days. 0 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −6.9% to 1.09M shares. 3.1 days to cover, ≈1.1% of shares.

  • TrendUPTREND

    21% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.TRIM3,060,960$3.8M
JANE STREET GROUP, LLCDOUBLED1,563,003$1.9M
GEODE CAPITAL MANAGEMENT, LLCTRIM1,326,914$1.6M
MILLENNIUM MANAGEMENT LLCDOUBLED1,204,921$1.5M
MARSHALL WACE, LLPDOUBLED1,014,778$1.2M
CITADEL ADVISORS LLCDOUBLED856,318$1.1M
STATE STREET CORPNEAR_EXIT516,750$635.6K
DIMENSIONAL FUND ADVISORS LPTRIM270,740$333.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026
12-month targets · 4 analysts

Price is below the lowest target. Median implies +203%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Mar 25, 2026Craig-Hallum
MAINTAIN
MAINTAINBuy
Aug 11, 2025BTIG
DOWNGRADE
DOWNGRADENeutral
Aug 7, 2025William Blair
DOWNGRADE
DOWNGRADEMarket Perform
Mar 12, 2025Stifel
MAINTAIN
MAINTAINBuy
Apr 23, 2024Stephens & Co.
REITERATE
REITERATEOverweight
Mar 13, 2024Stephens & Co.
REITERATE
REITERATEOverweight

Insider ledger

Form 4
$0
bought · 0 insiders
$8.3K
sold · 1 insider
DateInsiderTypeValue
Jun 17, 2026
Al-Wakeel Yasir B.
Director
AWARD30,421 sh
Jun 17, 2026
Al-Wakeel Yasir B.
Director
AWARD49,579 sh
Jun 17, 2026
BALTHROP PATRICK J
Director
AWARD30,421 sh
Jun 17, 2026
BALTHROP PATRICK J
Director
AWARD49,579 sh
Jun 17, 2026
Brooke William W
Director
AWARD49,579 sh
Jun 17, 2026
Brooke William W
Director
AWARD30,421 sh
Jun 17, 2026
Collins Cynthia
Director
AWARD30,421 sh
Jun 17, 2026
Collins Cynthia
Director
AWARD49,579 sh

Earnings setup

Estimates
Nov 10
reports in 15 days
−$0.08
EPS estimate, this quarter
−11%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.08-$0.09–-$0.08+0.0%$7.5M
Next Q-$0.07-$0.09–-$0.05+0.0%$7.4M
Current FY-$0.28-$0.30–-$0.25+0.0%$32.2M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
1,089,972
shares short
-6.9%
vs prior settlement
3.1
days to cover
≈1.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 SEC
Liontrust Investment Partners LLP, a UK-based investment firm, filed a Schedule 13D disclosing beneficial ownership of…
SC 13D — Impact 6/10
Oct 14, 2026 SEC
MaxCyte reported preliminary Q3 2026 core revenue of ~$8.1M (+26% YoY) and raised full-year 2026 revenue guidance to…
8-K — Impact 6/10
Sep 23, 2026 Other
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engi
Jun 30, 2026 Inst.
BlackRock, Inc. — TRIM
3,060,960 shares ($3.8M)
Jun 30, 2026 Inst.
JANE STREET GROUP, LLC — DOUBLED
1,563,003 shares ($1.9M)
Jun 17, 2026 Insider
Al-Wakeel Yasir B. was granted 30,421 shares
Director
Jun 17, 2026 Insider
Al-Wakeel Yasir B. was granted 49,579 shares
Director
Jun 17, 2026 Insider
BALTHROP PATRICK J was granted 30,421 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
MXCT Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Sep 23, 2026
Press release
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer
ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform…
Sep 11, 2026
Press release
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ROCKVILLE, Md., Sept. 11, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling…
Aug 12, 2026
Earnings
MaxCyte Reports Second Quarter 2026 Financial Results
ROCKVILLE, Md., Aug. 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling…
Aug 12, 2026
Earnings date
MXCT Q2 2026 Earnings Scheduled — 2026-08-12
May 12, 2026
Earnings date
MXCT Q1 2026 Earnings Scheduled — 2026-05-12

SecBot reports

3 filings · 1 press release · 2 bullish · 0 bearish · 1 neutral
All MXCT filing & press-release reports (4)